Dupixent® Reduces COPD Exacerbations in Phase III Study

Sanofi and Regeneron announced promising results for Dupixent® (dupilumab) in the treatment of chronic obstructive pulmonary disease (COPD) with type 2 inflammation. The phase III NOTUS study, presented at the American Thoracic Society (ATS) and published in the New England Journal of Medicine (NEJM), shows a significant reduction in exacerbations by 34% and a notable improvement in respiratory function.

Patients treated with Dupixent benefited from a reduction in moderate to severe acute exacerbations and an improvement in quality of life measured by specific scores. The safety results are consistent with previous approved indications for Dupixent.

Dupixent is currently under priority review by the United States Food and Drug Administration (FDA), with a decision expected by June 27, 2024. Applications for approval are also underway in the European Union and China .

This study could mark a significant advance in the treatment of COPD, a disease for which no new drug has been approved for more than ten years.